can semaglutide worsen depression and Risk: What Research Shows GLP-1 diabetes drugs could stop
Description
Patients who are not diabetic but need weight management assistance
Key clinical trials The clinical evidence supporting semaglutide in heart failure with preserved ejection fraction (HFpEF) and related conditions derives from a series of robust trials, ranging from cardiovascular outcome studies in T2D to targeted investigations in HFpEF with obesity and T2D
But so far, the studies of this and most other inflammation-related impact of GLP-1 drugs are restricted to animal (usually mouse or rat) models
It is important to remember that individual results may vary, and consistency and commitment to the program are key to achieving long-term success
